Englander Institute for Precision Medicine

Publications

Found 805 results
Author Title Type [ Year(Asc)]
2024
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H et al..  2024.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.. BMC Cancer. 23(Suppl 1):1256.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF et al..  2024.  Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.. Nat Aging.
Galassi C, Esteller M, Vitale I, Galluzzi L.  2024.  Epigenetic control of immunoevasion in cancer stem cells.. Trends Cancer.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 383:xi-xv.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 387:xiii-xvii.
Stenzl A, Armstrong AJ, Rogers E, Habr D, Walz J, Gleave M, Sboner A, Ghith J, Serfass L, Schuler KW et al..  2024.  Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.. Urol Pract. :101097UPJ0000000000000740.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Sternberg CN, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Banna GLuigi, Zengerling F, De Giorgi U, Gedye C, Masini C et al..  2024.  Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.. Eur Urol Focus.
Campia G, Beltrán-Visiedo M, Soler-Agesta R, Sato A, Bloy N, Zhao L, Liu P, Kepp O, Kroemer G, Galluzzi L et al..  2024.  Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line.. Methods Cell Biol. 189:153-168.
Soler-Agesta R, Ripollés-Yuba C, Marco-Brualla J, Moreno-Loshuertos R, Sato A, Beltrán-Visiedo M, Galluzzi L, Anel A.  2024.  Generation of transmitochondrial cybrids in cancer cells.. Methods Cell Biol. 189:23-40.
Suhre K.  2024.  Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions.. Cell Genom. 4(3):100506.
Suhre K, Chen Q, Halama A, Mendez K, Dahlin A, Stephan N, Thareja G, Sarwath H, Guturu H, Dwaraka VB et al..  2024.  A genome-wide association study of mass spectrometry proteomics using the Seer Proteograph platform.. bioRxiv.
Dai E, Chen X, Linkermann A, Jiang X, Kang R, Kagan VE, Bayir H, Yang WSeok, Garcia-Saez AJ, Ioannou MS et al..  2024.  A guideline on the molecular ecosystem regulating ferroptosis.. Nat Cell Biol.
Sanidad KZ, Rager SL, Carrow HC, Ananthanarayanan A, Callaghan R, Hart LR, Li T, Ravisankar P, Brown JA, Amir M et al..  2024.  Gut bacteria-derived serotonin promotes immune tolerance in early life.. Sci Immunol. 9(93):eadj4775.
Galassi C, Chan TA, Vitale I, Galluzzi L.  2024.  The hallmarks of cancer immune evasion.. Cancer Cell. 42(11):1825-1863.
Annabestani M, Sriram S, Caprio A, Janghorbani S, S Wong C, Sigaras A, Mosadegh B.  2024.  High-fidelity pose estimation for real-time extended reality (XR) visualization for cardiac catheterization.. Sci Rep. 14(1):26962.
Ranti D, Yu H, Wang YA, Bieber C, Strandgaard T, Salomé B, Houghton S, Kim J, Ravichandran H, Okulate I et al..  2024.  HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.. bioRxiv.
Catanzaro E, Demuynck R, Naessens F, Galluzzi L, Krysko DV.  2024.  Immunogenicity of ferroptosis in cancer: a matter of context? Trends Cancer.
Niso-Santano M, Fuentes JM, Galluzzi L.  2024.  Immunological aspects of central neurodegeneration.. Cell Discov. 10(1):41.
Kroemer G, Chan TA, Eggermont AMM, Galluzzi L.  2024.  Immunosurveillance in clinical cancer management.. CA Cancer J Clin. 74(2):187-202.
de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI et al..  2024.  Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.. Eur Urol.
Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B et al..  2024.  Impact of radiotherapy dose, fractionation and immunotherapeutic partner in a mouse model of HR+ mammary carcinogenesis.. J Natl Cancer Inst.
Gal J, Mosquera JMiguel, Robinson BD, Schlegel PN.  2024.  Incidental seminoma in nonobstructive azoospermia: a case report.. F S Rep. 5(2):211-213.
Chatterjee SS, Linares JF, Cid-Diaz T, Duran A, Khan MImran K, Osrodek M, Brady NJ, Reina-Campos M, Marzio A, Venkadakrishnan VBalaji et al..  2024.  Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.. Nat Commun. 15(1):9755.
Arnold M, Buyukozkan M, P Doraiswamy M, Nho K, Wu T, Gudnason V, Launer LJ, Wang-Sattler R, Adamski J, De Jager PL et al..  2024.  Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.. medRxiv.